Introduction
============

The risk of developing rheumatoid arthritis (RA), a common autoimmune disease characterized by inflammation and destruction of the joints, has long been known to be at least partially attributable to genetics. Recently, Gregersen and colleagues \[[@B1]\] reported that a common single nucleotide polymorphism (SNP) in the transcriptional regulatory gene *REL*confers a 1.2-fold greater risk of RA, on the basis of a solid and extensive investigation of a genome-wide association study (GWAS) in a large cohort of patients. Increased risk of similar magnitude has also been associated with SNPs in several other genes. Clearly the genetic basis of RA is complex, and polymorphisms in various genes have been associated with a greater risk of developing RA or of greater severity of the disease once an individual has RA.

The techniques of GWAS can now be applied to a wider and wider range of diseases, thanks to technological advances in identifying genetic polymorphisms in large groups of individuals, advances in genotyping (for example, Gregersen *et al.*\[[@B1]\] included only RA patients expressing antibodies to citrullinated peptides), stronger collaborations among investigators at multiple institutions, and the availability of more sophisticated statistical and computational approaches to analyzing extremely large datasets. The studies described by Gregersen and colleagues \[[@B1]\] certainly exemplify a collaborative approach backed up by considerable technology and advanced data analysis. Investigators at 12 different academic institutions and one company in three different countries are listed as coauthors on the work, and state-of-the-art technology was used to analyze the frequency of 278,502 SNPs in 2,418 North American patients and 4,504 North American controls of European origin. The total number of patients was divided into discovery and replication cohorts to add rigor to the analysis, and the statistical analysis of the results was highly stringent and used standard computerized approaches. In addition to making the new observation on association of a SNP in *REL*with RA, the study also revealed associations with the genes encoding cytotoxic T-lymphocyte antigen 4 (CTLA4) and B-cell lymphocyte kinase (BLK) and confirmed the association of other genetic polymorphisms with RA, including the human leukocyte antigen (HLA) region \[[@B2]\], the protein tyrosine phosphatase gene *PTPN22*\[[@B3]\] and the co-stimulatory protein gene *CD40*\[[@B4]\]. Interestingly, other than the HLA associations with RA, which are robust and have been observed in numerous studies, all of the associations observed here are modest, all in the range of a relative risk of 1.2.

Low risk genotypes lead to better understanding
===============================================

The capacity to detect very small differences between disease and control populations and the reporting of such associations clearly demonstrates that the low-hanging fruit of genetic disease associations has been picked and we are now harvesting the fruit from the top of the tree. But is there similar nutritive value for these less accessible fruits? As the cost of sequencing an individual\'s entire genome falls and increasing numbers of individuals obtain this information about themselves, will modest disease associations, such as those observed by Gregersen *et al*. \[[@B1]\], clutter up an otherwise clear picture of genetic risk? Will these genetic associations illuminate new targets for therapy? It is unlikely that the information derived here will be useful in making a diagnosis of RA, but could this work lead to a better understanding of the disease?

*REL*is a member of the NFκB family of transcriptional regulators that have a prominent role in inflammation. On this basis alone, the findings described here confirm much of the biology previously worked out for RA. Although there is clear overlap in the functions of the members of this family of transcriptional regulators, *REL*seems to have an important role in the survival of activated CD8^+^cells \[[@B5]\]. Thus, this work \[[@B1]\] might lead to a more nuanced understanding of the pathophysiology of RA that includes a more specific role for CD8^+^T cells in the pathogenesis of RA.

In addition to the genetic contribution to the risk of developing RA, other environmental risk factors clearly have a role, and it is likely that environmental factors will also interact with the genetic factors predisposing to development of RA. It has long been known that living in an urban environment confers a greater risk of developing RA than living in a more rural environment \[[@B6]-[@B8]\]. Dietary factors have been implicated in some studies, although these findings are not very consistent \[[@B9],[@B10]\]. Smoking is the single environmental factor that is most strongly and reproducibly linked with an increased risk of developing RA \[[@B9]\], although no interaction between smoking and known genetic risk factors has been observed \[[@B11],[@B12]\].

Where now for GWAS?
===================

As with so many technological advances, GWAS is now becoming \'routine\' and is producing information about genetic risk factors that confer less and less risk. Nonetheless, the value of the technique is clear and the potential for contributing to a much more detailed and nuanced understanding of the genetic risk factors, the pathogenesis of the disease and the potential for defining new therapeutic targets is great. So, despite the identification of factors that confer less and less risk for the development of RA, the biological implications of the findings indicate that GWAS may produce important insights and not just too much information.
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